ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

0L60 Shire Ads Rep 3

168.95
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shire Ads Rep 3 LSE:0L60 London Ordinary Share SHIRE ADR REPRESENTING 3 ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 168.95 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Shire plc Shire Plc : Total Voting Rights

01/02/2018 1:00pm

UK Regulatory


 
TIDMSHP 
 
 
   Total Voting Rights 
 
   February 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), 
in accordance with 5.6.1R of the Financial Conduct Authority's (the 
"FCA") Disclosure Guidance and Transparency Rules, notifies the market 
of the following: 
 
   As at January 31, 2018, the Company's issued ordinary share capital 
comprised 910,039,956 ordinary shares of 5 pence each with voting rights 
and a further 7,357,283 ordinary shares held in treasury. 
 
   Therefore, the total number of voting rights in the Company is 
910,039,956. This is the figure which should be used by shareholders as 
the denominator for the calculations by which they will determine if 
they are required to notify their interest in, or a change to their 
interest in, the Company under the FCA's Disclosure Guidance and 
Transparency Rules. 
 
   Sarah Rixon 
 
   Company Secretarial Assistant 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Christoph Brackmann   christoph.brackmann@shire.com    +41 795 432 359 
Robert Coates         rcoates@shire.com               +44 203 549 0874 
Sun Kim               sun.kim@shire.com                +1 617 588 8175 
Media 
Lisa Adler            lisa.adler@shire.com             +1 617 588 8607 
Katie Joyce           kjoyce@shire.com                 +1 781 482 2779 
 
 
   NOTES TO EDITORS 
 
   About Shire 
 
   Shire is the global leader in serving patients with rare diseases. We 
strive to develop best-in-class therapies across a core of rare disease 
areas including hematology, immunology, genetic diseases, neuroscience, 
and internal medicine with growing therapeutic areas in ophthalmics and 
oncology. Our diversified capabilities enable us to reach patients in 
more than 100 countries who are struggling to live their lives to the 
fullest. 
 
   We feel a strong sense of urgency to address unmet medical needs and 
work tirelessly to improve people's lives with medicines that have a 
meaningful impact on patients and all who support them on their journey. 
 
   www.shire.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Shire plc via Globenewswire 
 
 
 
 

(END) Dow Jones Newswires

February 01, 2018 08:00 ET (13:00 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

1 Year Shire Ads Rep 3 Chart

1 Year Shire Ads Rep 3 Chart

1 Month Shire Ads Rep 3 Chart

1 Month Shire Ads Rep 3 Chart

Your Recent History

Delayed Upgrade Clock